| __timestamp | Cytokinetics, Incorporated | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 17268000 | 13774000 |
| Thursday, January 1, 2015 | 19667000 | 22479000 |
| Friday, January 1, 2016 | 27823000 | 27388000 |
| Sunday, January 1, 2017 | 36468000 | 35610000 |
| Monday, January 1, 2018 | 31282000 | 49007000 |
| Tuesday, January 1, 2019 | 39610000 | 61139000 |
| Wednesday, January 1, 2020 | 52820000 | 68836000 |
| Friday, January 1, 2021 | 96803000 | 97592000 |
| Saturday, January 1, 2022 | 177977000 | 106903000 |
| Sunday, January 1, 2023 | 173612000 | 120998000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Cytokinetics, Incorporated and Vericel Corporation from 2014 to 2023. Over this period, Cytokinetics saw a staggering increase of over 900% in SG&A expenses, peaking in 2022. Meanwhile, Vericel's expenses grew by approximately 780%, with a notable rise in 2023. This trend reflects the companies' strategic investments in growth and development. Cytokinetics' expenses surged in 2022, possibly due to increased R&D activities, while Vericel's steady rise suggests a focus on expanding market presence. Understanding these financial dynamics offers insights into how biotech firms allocate resources to drive innovation and maintain competitiveness. As the industry evolves, monitoring such trends becomes essential for stakeholders and investors alike.
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of GSK plc and Vericel Corporation
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Cytokinetics, Incorporated
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Vericel Corporation
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Who Optimizes SG&A Costs Better? Alkermes plc or Vericel Corporation
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Vericel Corporation
Comparing SG&A Expenses: Vericel Corporation vs MiMedx Group, Inc. Trends and Insights